EP Patent

EP2130536A1 — N3 alkylated benzimidazole derivatives as mek inhibitors

Assigned to Array Biopharma Inc · Expires 2009-12-09 · 16y expired

What this patent protects

Disclosed are compounds of the formula I and pharmaceutically acceptable salts thereof, wherein W, R 1 , R 2 , R 7 , R 8 , R 9 and R 10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseas…

USPTO Abstract

Disclosed are compounds of the formula I and pharmaceutically acceptable salts thereof, wherein W, R 1 , R 2 , R 7 , R 8 , R 9 and R 10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals.

Drugs covered by this patent

Patent Metadata

Patent number
EP2130536A1
Jurisdiction
EP
Classification
—
Expires
2009-12-09
Drug substance claim
No
Drug product claim
No
Assignee
Array Biopharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.